Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2525556 | 0.98 | MAPK14 (0.53) | MAPK14FFAR1THRATHRBCETP | |
| SCHEMBL23296153 | 0.91 | SLC13A5 (0.56) | MAPK14FFAR1THRATHRBCETP | |
| SCHEMBL4437946 | 0.90 | THRA (0.58) | MAPK14FFAR1THRATHRBCETP | |
| SCHEMBL28475012 | 0.88 | VNN1 (0.56) | MAPK14FFAR1CETPKDM5AKDM4C | |
| SCHEMBL27834591 | 0.88 | VNN1 (0.54) | MAPK14FFAR1CETPKDM5AKDM4C | |
| SCHEMBL11546048 | 0.85 | CHRM2 (0.51) | MAPK14CETPKDM5AKDM4CKDM5B | |
| SCHEMBL6685564 | 0.85 | EPHX1 (0.52) | MAPK14CETPKDM5AKDM4CKDM5B | |
| SCHEMBL1792094 | 0.85 | CNR1 (0.50) | MAPK14FFAR1CETPKDM5AKDM4C | |
| SCHEMBL1271844 | 0.84 | FFAR1 (0.67) | MAPK14FFAR1FFAR4CHRM2CHRM1 | |
| SCHEMBL4429928 | 0.84 | THRA (0.55) | MAPK14FFAR1THRATHRBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | MERCK SERONO SA (CH) | 2004-12-16 | — | — | US | disclosed |
| EP-1439837-A1 | PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003035064-A1 | PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-05-01 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | PTGER4, PTGER2, PTGER1 | MAPK14 1680/4885FFAR1 350/4885THRA 2251/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MAPK14 256/4885FFAR1 1632/4885THRA 3057/4885 |
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | MAPK14 878/4885FFAR1 3370/4885THRA 2429/4885 |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | MAPK14 2929/4885FFAR1 863/4885THRA 3770/4885 |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | MAPK14 2845/4885FFAR1 3946/4885THRA 2640/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MAPK14 256/4885FFAR1 1632/4885THRA 3057/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | MAPK14 4565/4885FFAR1 2840/4885THRA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.